Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CBA-1535 With or Without Pembrolizumab in Solid Tumors
jRCT2031210708Phase 1Recruiting
- Sponsor
- Chiome Bioscience Inc.
- Start
- Jun 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CBA-1535 in Non-hematologic malignancy (2 arms), sponsored by Chiome Bioscience Inc. Primary endpoints: Dose Limiting Toxicity and Adverse Event. Started Jun 2022; status: recruiting.
02
Drugs
CBA-1535
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031210708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210708.